Page 6 - Wuxi Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Wuxi bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Wuxi Bio Today - Breaking & Trending Today
Apr 5, 2021 12:23pm Chime Biologics second biologics site, pictured above, will lift total manufacturing capacity to 140,000 liters, the CDMO said.(PR Newswire/Chime Biologics) After locking up a $125 million Series A in early 2020, China-based CDMO Chime Biologics has raised another $65 million to help build and kit out a second plant in Wuhan, China. The $190 million investment will fuel an expansion over the next five years at its site in Wuhan, taking capacity there to 140,000 liters. The new plant will join Chime s first facility there, which is built around a modular manufacturing system from Cytiva Life Sciences. Chime counts monoclonal and bispecific antibodies, fusion and conjugated proteins, and enzymes among its manufacturing repertoire, according to the company’s website. ....
Pfizer sells biosimilars plant in China to Wuxi biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.
Pfizer halts biosimilar programs in crowded China market, sells plant to WuXi Biologics fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Published: Mar 11, 2021 By Alex Keown Saniona, a rare disease-focused company based in Sweden, received feedback from the U.S. Food and Drug Administration (FDA) on a path forward for its hypothalamic obesity (HO) drug Tesomet. Based on guidance from the regulatory agency, Saniona is planning a Phase IIb study in this indication in the first half of this year. “There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” Rudolf Baumgartner, Chief Medical Officer and Head of Clinical Development at Saniona said in a statement. “We are encouraged by this feedback from the FDA and look forward to continuing a constructive dialogue with them as we prepare to initiate our Phase IIb clinical trial with Tesomet.” ....
Press release content from Business Wire. The AP news staff was not involved in its creation. Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline March 8, 2021 GMT ALAMEDA, Calif. & SHANGHAI (BUSINESS WIRE) Mar 8, 2021 Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind CABOMETYX ® (cabozantinib), its flagship product and global oncology franchise, which received its fourth approval from the U.S. Food and Drug Administration in January. ....